JSPR

Jasper Therapeutics Inc

Add to Watchlist

Advanced Chart

3.330

-0.04(-1.187%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

3.480

Open

3.400

VWAP

3.36

Vol

350.33K

Mkt Cap

50.02M

Low

3.2639

Amount

1.18M

EV/EBITDA(TTM)

Total Shares

15.09M

1.22M

EV/OCF(TTM)

P/S(TTM)

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

9 Analyst Rating

1328.53% Upside

Wall Street analysts forecast JSPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JSPR is 47.57 USD with a low forecast of 15.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

0 Hold

0 Sell

Strong Buy

1328.53% Upside

Current: 3.330

Low

15.00

Averages

47.57

High

70.00

1328.53% Upside

Current: 3.330

Low

15.00

Averages

47.57

High

70.00

RBC Capital

Outperform -> Sector Perform

downgrade

$46 -> $5

2025-07-08

Reason

RBC Capital

Price Target

$46 -> $5

2025-07-08

downgrade

Outperform -> Sector Perform

Reason

RBC Capital downgraded Jasper Therapeutics to Sector Perform from Outperform with a price target of $5, down from $46.

Citizens JMP

Outperform

NULL

downgrade

$70 -> $12

2025-07-08

Reason

Citizens JMP

Price Target

$70 -> $12

2025-07-08

downgrade

Outperform

NULL

Reason

Citizens JMP lowered the firm's price target on Jasper Therapeutics to $12 from $70 and keeps an Outperform rating on the shares after the company disclosed updates for the Phase 1b/2a BEACON study of briquilimab for chronic spontaneous urticaria. The CSU readout fell flat due to a likely manufacturing issue and the company will try again in 4Q25, which further increases pressure from a financing overhang, the analyst tells investors in a research note. Based on new data from the interim update from the single dose and early look at the open-label extension, the firm continues to have confidence in our view that briquilimab can be differentiated on a dosing schedule and risk/benefit profile.

H.C. Wainwright

Buy

downgrade

$40 -> $20

2025-07-07

Reason

H.C. Wainwright

Price Target

$40 -> $20

2025-07-07

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Jasper Therapeutics to $20 from $40 and keeps a Buy rating on the shares after the company's "surprising update" that the 240 mg every 8 week and 240 mg loading dose plus 180 mg every 8 week cohorts in the BEACON trial evaluating briquilimab for treatment of chronic spontaneous urticaria were impacted by issues with one drug product lot. The firm updated its model to shift its launch estimates for CSU and chronic inducible urticaria in the U.S. to 2030 and 2031, respectively, and to account for the company's cost-cutting plans and lower operating expenses in 2025. However, the firm still believes the company will need to raise capital and currently estimates a $5M raise.

William Blair

Outperform -> Market Perform

downgrade

2025-07-07

Reason

William Blair

Price Target

2025-07-07

downgrade

Outperform -> Market Perform

Reason

William Blair downgraded Jasper Therapeutics to Market Perform from Outperform after the company reported updated data from the BEACON study and preliminary data from the open-label extension of briquilimab in chronic spontaneous urticaria. Jasper also disclosed that some of the multi-dose cohorts from BEACON were impacted by an inactive drug product lot and that development of briquilimab in asthma has been halted because the same inactive drug product lot was used for all patients in the ETESIAN asthma challenge study, the analyst noted. The firm is downgrading shares as a result of this "setback," citing a lack of clarity around both the funding overhang and concerns related to drug product manufacturing.

BTIG

Buy

downgrade

$64 -> $20

2025-07-07

Reason

BTIG

Price Target

$64 -> $20

2025-07-07

downgrade

Buy

Reason

BTIG lowered the firm's price target on Jasper Therapeutics to $20 from $64 and keeps a Buy rating on the shares. The Phase 1b/2a BEACON trial update evaluating briquilimab in chronic spontaneous urticaria included a faulty drug lot that impacted efficacy, the analyst tells investors in a research note. The firm says that while the specific issue is yet to be determined, Jasper paused the asthma trial, with the Phase 2b study start in CSU now expected in mid 2026. Despite the pushed out timelines and the asthma catalyst taken off the table, BTIG continues to see briquilmab as a safe and active drug with "compelling" efficacy.

Cantor Fitzgerald

Overweight -> Neutral

downgrade

2025-07-07

Reason

Cantor Fitzgerald

Price Target

2025-07-07

downgrade

Overweight -> Neutral

Reason

Cantor Fitzgerald downgraded Jasper Therapeutics to Neutral from Overweight.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Jasper Therapeutics Inc (JSPR.O) is -0.78, compared to its 5-year average forward P/E of -3.74. For a more detailed relative valuation and DCF analysis to assess Jasper Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.74

Current PE

-0.78

Overvalued PE

-0.43

Undervalued PE

-7.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.58

Current EV/EBITDA

-0.05

Overvalued EV/EBITDA

1.67

Undervalued EV/EBITDA

-4.82

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.57

Current PS

0.00

Overvalued PS

3.58

Undervalued PS

-2.43